MarketPR
Food and Drug Administration has reversed its opposition to a closely watched gene therapy for Huntington's disease developed by biotech company UniQure, clearing a direct path for UniQure to file for U.S.
The agency's turnaround represents a meaningful inflection for a disease community that has watched therapeutic candidates stall or fail, and positions UniQure for a pivotal regulatory moment in the American market.
Filing Window for UniQure The reversal is significant precisely because the FDA had previously blocked the path.
Regulatory opposition — not just a lengthy review — is the harder obstacle; removing it shifts the question from "if" to "when" UniQure submits its filing.
Keep reading